The practical consequence is that US biotech investors have built a habit of treating insider filings as near-real-time sentiment indicators. Sometimes that is sensible. Sometimes it is merely a way to outsource due diligence to people who are not allowed to tell you what they know.
What the evidence says, and what it does not
Academic evidence supports insider buys as a broad signal, not a biotech oracle
The academic literature generally finds abnormal returns following insider purchases, particularly in smaller firms and in periods of high information asymmetry. That is the good news. The less exciting news is that these are average effects across samples, not a promise that every pre-event biotech purchase predicts a positive FDA outcome.
Biotech is also vulnerable to selection bias in storytelling. Investors remember the dramatic wins, the insider who bought before an approval and looked clairvoyant. They forget the quieter cases where insiders bought, the FDA delayed or rejected, and the stock spent the next year introducing shareholders to the concept of dilution. A proper sample would compare all meaningful pre-PDUFA insider buys against a control set of similar companies without buys, adjusted for size, cash runway, indication, and prior volatility. That is the sort of exercise that improves understanding and ruins cocktail-party anecdotes.
The strongest practical inference is often about expected value, not certainty
This is the most useful framing. A meaningful insider purchase ahead of a PDUFA date does not necessarily say, "approval is likely". It may say, "the insider believes the market is underestimating expected value across approval, delay, and rejection scenarios". That is subtler and more realistic.
For example, if management believes the downside after a complete response letter is cushioned by cash, partnership optionality, or a fixable manufacturing issue, buying before the event can still make sense. Investors who read every pre-PDUFA purchase as a pure approval bet are simplifying a multi-branch decision tree into a coin toss. Markets love a coin toss because it fits in a headline. Biology and regulation remain less cooperative.
A framework for investors tracking these trades now
Build a checklist, not a myth
A sensible framework for evaluating pre-FDA insider buying in biotech would include:
- Transaction type: discretionary open-market purchase versus plan-based or indirect transaction.
- Buyer identity: operational insider, scientific founder, finance executive, or independent director.
- Economic weight: meaningful relative to salary and prior holdings.
- Clustering: one buyer or several.
- Timing: how close to the PDUFA date, and whether the company was likely in a blackout for part of that period.
- Cash runway: enough to survive a negative outcome without immediate financing.
- Regulatory context: clean review versus known manufacturing, inspection, or safety issues.
- Valuation context: is the stock already pricing high approval odds.
- Footnotes: 10b5-1 plan disclosures, indirect ownership, family trusts, and other details that make the difference between signal and paperwork.
This checklist is less thrilling than a tale of insiders loading up before a green light from the FDA. It is also more likely to preserve capital.
The best case studies are the ones with enough detail to disappoint romantics
When this pattern works well as a signal, the setup usually looks plain rather than cinematic. A small or mid-cap biotech with one major near-term catalyst, a manageable cash position, no obvious unresolved manufacturing overhang, and one or more senior insiders making economically meaningful open-market purchases after a long period of inactivity. The market notices. The stock often firms. If approval follows, the filing is later treated as prophecy.
Prophecy is usually just a board-approved trade ticket plus a lot of retrospective storytelling. Still, if one must choose between the stories told by investor-relations decks and the stories told by executives spending their own money, the latter tends to be the less decorative source.
The open question is empirical and worth testing properly: do pre-PDUFA insider buys outperform generic insider buys in biotech after controlling for firm size, cash runway, and prior drawdown? Our dataset for this article did not include live query output, so the honest value for any house statistic is n/a. That leaves a concrete next step. Build the sample, separate discretionary buys from plan trades, tag FDA catalyst dates, and see whether the folklore survives contact with a full distribution rather than three famous anecdotes.
